The purpose of this study was to assess the effectiveness and side effects of pegylated liposomal doxorubicin (PLD) and epirubicin in neoadjuvant treatment for HER2-negative breast cancer. The authors performed a retrospective analysis of 107 patients diagnosed with HER2-negative breast cancer who underwent TA (PLD 35 mg/m2, docetaxel 75 mg/m2) or TE (epirubicin 100 mg/m2, docetaxel 75 mg/m2) neoadjuvant chemotherapy (NAC) from January 2021 to December 2022. PLD was administered in 57 instances, while epirubicin was used in 50 cases. The clinicopathological features, chemotherapy effects, and adverse responses of these individuals were examined, and logistic regression was applied to determine the parameters defining the effectiveness of NAC. The clinicopathological characteristics of the PLD and epirubicin groups were consistent, and there was no statistical difference. Also, there was no statistical difference in the efficacy of NAC between the two groups. Leukopenia, hair loss, digestive tract responses, and irregular electrocardiograms were dramatically decreased in the PLD group compared to the epirubicin group. However, hand-foot syndrome and hypersensitivity were significantly increased, with statistical relevance. PLD has the same efficacy as traditional epirubicin in NAC for HER2-negative breast cancer.
{"title":"Comparison of the efficacy and safety of pegylated liposomal doxorubicin and epirubicin in neoadjuvant chemotherapy for HER2-negative breast cancer: a real-world case–control study","authors":"Lixian Yang, Shiyu Zhang, Lei Zheng, Pengpeng Pu, Xiaowei Li, Lining Jia","doi":"10.1097/ij9.0000000000000125","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000125","url":null,"abstract":"\u0000 \u0000 The purpose of this study was to assess the effectiveness and side effects of pegylated liposomal doxorubicin (PLD) and epirubicin in neoadjuvant treatment for HER2-negative breast cancer.\u0000 \u0000 \u0000 \u0000 The authors performed a retrospective analysis of 107 patients diagnosed with HER2-negative breast cancer who underwent TA (PLD 35 mg/m2, docetaxel 75 mg/m2) or TE (epirubicin 100 mg/m2, docetaxel 75 mg/m2) neoadjuvant chemotherapy (NAC) from January 2021 to December 2022. PLD was administered in 57 instances, while epirubicin was used in 50 cases. The clinicopathological features, chemotherapy effects, and adverse responses of these individuals were examined, and logistic regression was applied to determine the parameters defining the effectiveness of NAC.\u0000 \u0000 \u0000 \u0000 The clinicopathological characteristics of the PLD and epirubicin groups were consistent, and there was no statistical difference. Also, there was no statistical difference in the efficacy of NAC between the two groups. Leukopenia, hair loss, digestive tract responses, and irregular electrocardiograms were dramatically decreased in the PLD group compared to the epirubicin group. However, hand-foot syndrome and hypersensitivity were significantly increased, with statistical relevance.\u0000 \u0000 \u0000 \u0000 PLD has the same efficacy as traditional epirubicin in NAC for HER2-negative breast cancer.\u0000","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"88 7-8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139848990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The purpose of this study was to assess the effectiveness and side effects of pegylated liposomal doxorubicin (PLD) and epirubicin in neoadjuvant treatment for HER2-negative breast cancer. The authors performed a retrospective analysis of 107 patients diagnosed with HER2-negative breast cancer who underwent TA (PLD 35 mg/m2, docetaxel 75 mg/m2) or TE (epirubicin 100 mg/m2, docetaxel 75 mg/m2) neoadjuvant chemotherapy (NAC) from January 2021 to December 2022. PLD was administered in 57 instances, while epirubicin was used in 50 cases. The clinicopathological features, chemotherapy effects, and adverse responses of these individuals were examined, and logistic regression was applied to determine the parameters defining the effectiveness of NAC. The clinicopathological characteristics of the PLD and epirubicin groups were consistent, and there was no statistical difference. Also, there was no statistical difference in the efficacy of NAC between the two groups. Leukopenia, hair loss, digestive tract responses, and irregular electrocardiograms were dramatically decreased in the PLD group compared to the epirubicin group. However, hand-foot syndrome and hypersensitivity were significantly increased, with statistical relevance. PLD has the same efficacy as traditional epirubicin in NAC for HER2-negative breast cancer.
{"title":"Comparison of the efficacy and safety of pegylated liposomal doxorubicin and epirubicin in neoadjuvant chemotherapy for HER2-negative breast cancer: a real-world case–control study","authors":"Lixian Yang, Shiyu Zhang, Lei Zheng, Pengpeng Pu, Xiaowei Li, Lining Jia","doi":"10.1097/ij9.0000000000000125","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000125","url":null,"abstract":"\u0000 \u0000 The purpose of this study was to assess the effectiveness and side effects of pegylated liposomal doxorubicin (PLD) and epirubicin in neoadjuvant treatment for HER2-negative breast cancer.\u0000 \u0000 \u0000 \u0000 The authors performed a retrospective analysis of 107 patients diagnosed with HER2-negative breast cancer who underwent TA (PLD 35 mg/m2, docetaxel 75 mg/m2) or TE (epirubicin 100 mg/m2, docetaxel 75 mg/m2) neoadjuvant chemotherapy (NAC) from January 2021 to December 2022. PLD was administered in 57 instances, while epirubicin was used in 50 cases. The clinicopathological features, chemotherapy effects, and adverse responses of these individuals were examined, and logistic regression was applied to determine the parameters defining the effectiveness of NAC.\u0000 \u0000 \u0000 \u0000 The clinicopathological characteristics of the PLD and epirubicin groups were consistent, and there was no statistical difference. Also, there was no statistical difference in the efficacy of NAC between the two groups. Leukopenia, hair loss, digestive tract responses, and irregular electrocardiograms were dramatically decreased in the PLD group compared to the epirubicin group. However, hand-foot syndrome and hypersensitivity were significantly increased, with statistical relevance.\u0000 \u0000 \u0000 \u0000 PLD has the same efficacy as traditional epirubicin in NAC for HER2-negative breast cancer.\u0000","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":" 38","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139789352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-25DOI: 10.1097/01.ij9.0001009972.89756.65
{"title":"Spontaneous splenic artery rupture in a patient with an unclassified malignant spindle cell tumor of the spleen: report of a case: Expression of Concern","authors":"","doi":"10.1097/01.ij9.0001009972.89756.65","DOIUrl":"https://doi.org/10.1097/01.ij9.0001009972.89756.65","url":null,"abstract":"","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"118 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140495467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-05DOI: 10.1097/ij9.0000000000000117
E. Weledji, Luca Gianotti, Massimo Oldani, F. Uggeri
Sarcopenia is the subclinical loss of skeletal muscle and strength and has been extensively studied in both cancer and surgical patients. Patients with sarcopenia are particularly vulnerable to major physiological stressors including surgery and surgical complications. Sarcopenia has thus gained significant recognition as an important prognostic factor for both complications and survival in cancer patients. The aim of this review was to evaluate the current literature on the effect of sarcopenia on the treatment and prognosis of pancreatic cancer. The prevalence of sarcopenia in pancreatic cancer patients range between 20 and 65% due to the heterogeneous groups of patients, difference in disease stage, and the different methods of measuring sarcopenia. Sarcopenia would be more accurately assessed by utilizing both imaging and clinical data, such as frailty. Although malnutrition could be responsible for the attenuated healing process of pancreatic anastomosis the relationship between sarcopenia and outcome following pancreaticoduodenectomy is debated. Most studies showed a higher risk of postoperative pancreatic fistula formation in patients with concurrent sarcopenia and high fat mass (sarcopenic obesity). Sarcopenia seems generally to be associated with lower survival. The assessment of sarcopenia can therefore lead to changes in management strategy, patient selection, and improved informed consent prior to surgical resection of pancreatic cancer. An improved prediction of clinically relevant pancreatic fistula formation after pancreatic surgery using preoperative computed tomography scan, including a fistula risk score using sarcopenic obesity and subcutaneous fat area will be useful. Although treatment for sarcopenia still remains an area of research a protocol to improve nutrition and fitness preoperatively may improve sarcopenia and surgical outcome.
{"title":"The implications of sarcopenia in the treatment and prognosis of pancreatic cancer","authors":"E. Weledji, Luca Gianotti, Massimo Oldani, F. Uggeri","doi":"10.1097/ij9.0000000000000117","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000117","url":null,"abstract":"Sarcopenia is the subclinical loss of skeletal muscle and strength and has been extensively studied in both cancer and surgical patients. Patients with sarcopenia are particularly vulnerable to major physiological stressors including surgery and surgical complications. Sarcopenia has thus gained significant recognition as an important prognostic factor for both complications and survival in cancer patients. The aim of this review was to evaluate the current literature on the effect of sarcopenia on the treatment and prognosis of pancreatic cancer. The prevalence of sarcopenia in pancreatic cancer patients range between 20 and 65% due to the heterogeneous groups of patients, difference in disease stage, and the different methods of measuring sarcopenia. Sarcopenia would be more accurately assessed by utilizing both imaging and clinical data, such as frailty. Although malnutrition could be responsible for the attenuated healing process of pancreatic anastomosis the relationship between sarcopenia and outcome following pancreaticoduodenectomy is debated. Most studies showed a higher risk of postoperative pancreatic fistula formation in patients with concurrent sarcopenia and high fat mass (sarcopenic obesity). Sarcopenia seems generally to be associated with lower survival. The assessment of sarcopenia can therefore lead to changes in management strategy, patient selection, and improved informed consent prior to surgical resection of pancreatic cancer. An improved prediction of clinically relevant pancreatic fistula formation after pancreatic surgery using preoperative computed tomography scan, including a fistula risk score using sarcopenic obesity and subcutaneous fat area will be useful. Although treatment for sarcopenia still remains an area of research a protocol to improve nutrition and fitness preoperatively may improve sarcopenia and surgical outcome.","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"49 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139382301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1097/ij9.0000000000000124
{"title":"Spontaneous splenic artery rupture in a patient with an unclassified malignant spindle cell tumor of the spleen: report of a case: expression of concern","authors":"","doi":"10.1097/ij9.0000000000000124","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000124","url":null,"abstract":"","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"27 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139189825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1097/ij9.0000000000000123
Márk Stempler, Dejan Dobi, Nóra Ledó
Entrectinib has been approved and increasingly administered for the treatment of non-small cell lung cancer, especially with intracranial metastasis. Although previous clinical studies have confirmed its safety, disproportionality analysis showed unusually high potential adverse renal effects. We present a case of a 71-year-old woman with pulmonary adenocarcinoma who developed severe renal function impairment during the treatment with entrectinib. Urinary sediment examination revealed leukocyte casts, while urinary culture was negative, suggesting the presence of possible tubulointerstitial nephritis (TIN). A kidney biopsy was performed, and the diagnosis of TIN was confirmed. The administration of oral methylprednisolone improved renal function. Protein kinase inhibitors might lead to renal function impairment in several different ways. It is of utmost importance to differentiate between the underlying pathomechanism, which is often challenging. TIN is a potentially reversible condition when treated appropriately. In the case of renal function impairment during entrectinib therapy, the possibility of TIN should be considered, and a kidney biopsy should be performed since corticosteroid therapy might improve renal function.
恩替利尼已被批准用于治疗非小细胞肺癌，尤其是颅内转移的肺癌，并且应用越来越广泛。尽管之前的临床研究证实了其安全性，但比例失调分析显示其潜在的肾脏不良反应异常高。 我们报告了一例 71 岁女性肺腺癌患者在接受恩替替尼治疗期间出现严重肾功能损害的病例。尿沉渣检查发现白细胞铸型，而尿培养阴性，提示可能存在肾小管间质性肾炎（TIN）。患者接受了肾活检，确诊为肾小管间质性肾炎（TIN）。口服甲基强的松龙改善了肾功能。 蛋白激酶抑制剂可能以多种不同方式导致肾功能损害。最重要的是要区分潜在的病理机制，而这往往具有挑战性。如果治疗得当，TIN 是一种潜在的可逆性疾病。 如果在恩替替尼治疗期间出现肾功能损害，则应考虑 TIN 的可能性，并应进行肾活检，因为皮质类固醇治疗可能会改善肾功能。
{"title":"Entrectinib-induced tubulointerstitial nephritis: a case report","authors":"Márk Stempler, Dejan Dobi, Nóra Ledó","doi":"10.1097/ij9.0000000000000123","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000123","url":null,"abstract":"Entrectinib has been approved and increasingly administered for the treatment of non-small cell lung cancer, especially with intracranial metastasis. Although previous clinical studies have confirmed its safety, disproportionality analysis showed unusually high potential adverse renal effects. We present a case of a 71-year-old woman with pulmonary adenocarcinoma who developed severe renal function impairment during the treatment with entrectinib. Urinary sediment examination revealed leukocyte casts, while urinary culture was negative, suggesting the presence of possible tubulointerstitial nephritis (TIN). A kidney biopsy was performed, and the diagnosis of TIN was confirmed. The administration of oral methylprednisolone improved renal function. Protein kinase inhibitors might lead to renal function impairment in several different ways. It is of utmost importance to differentiate between the underlying pathomechanism, which is often challenging. TIN is a potentially reversible condition when treated appropriately. In the case of renal function impairment during entrectinib therapy, the possibility of TIN should be considered, and a kidney biopsy should be performed since corticosteroid therapy might improve renal function.","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"59 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139193711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-22DOI: 10.1097/ij9.0000000000000120
Rufus Smits, Ilona Domracheva, Baiba Turovska
Breast cancer is the most common invasive cancer and colorectal cancer (CRC) the second most diagnosed malignancy in women worldwide. In men CRC is the third most common cancer. Despite the recent advances in targeted therapy, the clinical efficacy is often limited, noncurative, with a high toxicity profile, and exorbitant costs. Therefore, there is a growing interest in identifying natural compounds that are safe and affordable as adjunctive treatments to the conventional therapy currently offered for these patients. Curcumin from the roots of the Curcuma longa, is one such compound that has become one of the leading and most studied natural medicines for its role in cancer prevention and powerful antioxidant activity. However, its fast metabolism, low bioavailability, and the lack of specificity call for curcumin analogues to be synthesized with increased potency and higher specificity. In search of lead compounds in the present study the cytotoxic effects of curcumin and 14 heterocyclic curcumin derivatives have been screened using the MTT assay on two cancer cell lines HCT-116 and MDA-MB-231 and also on the normal GM08402 (human fibroblast) cell line. Electrochemical oxidation potentials were determined for selected compounds to reveal their electron-donating capacity and as a general indicator of their radical scavenging ability. Two dihydropyridone lead compounds have been identified which compared to curcumin have higher cytotoxicity on both cancer cell lines and at the same time with reduced cytotoxicity on the normal cell line.
{"title":"Cytotoxicity of dihydropyridone and dihydropyrimidone curcumin derivatives against colon (HCT-116) and breast (MDA-MB-231) cancer cell lines","authors":"Rufus Smits, Ilona Domracheva, Baiba Turovska","doi":"10.1097/ij9.0000000000000120","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000120","url":null,"abstract":"Breast cancer is the most common invasive cancer and colorectal cancer (CRC) the second most diagnosed malignancy in women worldwide. In men CRC is the third most common cancer. Despite the recent advances in targeted therapy, the clinical efficacy is often limited, noncurative, with a high toxicity profile, and exorbitant costs. Therefore, there is a growing interest in identifying natural compounds that are safe and affordable as adjunctive treatments to the conventional therapy currently offered for these patients. Curcumin from the roots of the Curcuma longa, is one such compound that has become one of the leading and most studied natural medicines for its role in cancer prevention and powerful antioxidant activity. However, its fast metabolism, low bioavailability, and the lack of specificity call for curcumin analogues to be synthesized with increased potency and higher specificity. In search of lead compounds in the present study the cytotoxic effects of curcumin and 14 heterocyclic curcumin derivatives have been screened using the MTT assay on two cancer cell lines HCT-116 and MDA-MB-231 and also on the normal GM08402 (human fibroblast) cell line. Electrochemical oxidation potentials were determined for selected compounds to reveal their electron-donating capacity and as a general indicator of their radical scavenging ability. Two dihydropyridone lead compounds have been identified which compared to curcumin have higher cytotoxicity on both cancer cell lines and at the same time with reduced cytotoxicity on the normal cell line.","PeriodicalId":506384,"journal":{"name":"International Journal of Surgery Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139247624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：